Target intelligence / Profile preview

RAB4B-EGLN2 readthrough long non-coding RNA (RAB4B-EGLN2)

Target
RAB4B-EGLN2
Molecular classification
Long non-coding RNA (lncRNA), Readthrough transcript
01

Overview

RAB4B-EGLN2 readthrough long non-coding RNA is a naturally occurring RNA transcript resulting from read-through transcription between the neighboring RAB4B (RAB4B, member of the RAS oncogene family) and EGLN2 (egl nine homolog 2) genes on chromosome 19. This readthrough transcript is a candidate for nonsense-mediated mRNA decay (NMD) and is therefore unlikely to produce a protein product. As a long non-coding RNA (lncRNA), it is not known to function as a receptor, enzyme, or other classical drug target. Some studies have associated this locus or related lncRNAs with hepatocellular carcinoma, but the biological function of this specific transcript remains unclear and largely uncharacterized. There are no known drugs targeting this molecule, no defined mechanisms of action, no established biomarkers, and no reported safety concerns specifically associated with RAB4B-EGLN2[1][3][5][8].

Other names
RERT-lncRNARAB4B-EGLN2 readthroughRAB4B-EGLN2 readthrough long non-coding RNARAB4B-EGLN2 readthrough (NMD candidate)RAB4B-EGLN2 readthrough (non-protein coding)[1][5]
02

Biological functions

Candidate for nonsense-mediated mRNA decay (NMD)[1][5]No direct biological function established as a lncRNA
03

Disease associations

Cancer (implicated in hepatocellular carcinoma)[1][8]

Beyond the preview

Go deeper on RAB4B-EGLN2 readthrough long non-coding RNA (RAB4B-EGLN2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAB4B-EGLN2 readthrough long non-coding RNA (RAB4B-EGLN2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call